Improving CAR T cell therapy for brain tumors using a mouse model
Brain Tumor CAR T Mouse Model
['FUNDING_R03'] · SEATTLE CHILDREN'S HOSPITAL · NIH-11012811
This study is working on a new way to make CAR T cell therapy better for people with aggressive brain tumors by using specially designed mice to see how these modified immune cells can more effectively find and attack cancer cells.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SEATTLE CHILDREN'S HOSPITAL (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11012811 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new mouse model to enhance chimeric antigen receptor (CAR) T cell therapy specifically for malignant brain tumors. By genetically modifying T cells to better recognize and attack cancer cells, the study aims to overcome the challenges faced by CAR T therapy in treating brain tumors. The innovative mouse model will allow researchers to observe tumor growth and the behavior of CAR T cells in a realistic environment, using advanced imaging techniques to gain insights into how these therapies can be improved for patients. The ultimate goal is to optimize treatment strategies for high-grade gliomas, which are particularly aggressive brain tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade gliomas, particularly children and adults who have limited treatment options.
Not a fit: Patients with brain tumors that are not high-grade gliomas or those who are not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR T cell therapies for patients with malignant brain tumors, potentially improving survival rates and quality of life.
How similar studies have performed: While CAR T cell therapy has shown success in treating other cancers like leukemia and lymphoma, its application to brain tumors is still being explored, making this approach novel.
Where this research is happening
SEATTLE, UNITED STATES
- SEATTLE CHILDREN'S HOSPITAL — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUST, JULIANE — SEATTLE CHILDREN'S HOSPITAL
- Study coordinator: GUST, JULIANE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy